{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:50:51Z","timestamp":1787068251109,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016958","name":"Office of Research Infrastructure Programs, National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD021527"],"award-info":[{"award-number":["S10OD021527"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI115691"],"award-info":[{"award-number":["R01 AI115691"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","award":["DE-AC02-06CH11357"],"award-info":[{"award-number":["DE-AC02-06CH11357"]}],"id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008552","name":"Brigham Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 GM124165"],"award-info":[{"award-number":["P30 GM124165"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ijpddr.2021.05.002","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T14:36:34Z","timestamp":1622817394000},"page":"140-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Rational approach to drug discovery for human schistosomiasis"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-8559","authenticated-orcid":false,"given":"Philip T.","family":"LoVerde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevan N.","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3517-6033","authenticated-orcid":false,"given":"Alexander B.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayce","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric D.","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy JC.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanton F.","family":"McHardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2021.05.002_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4269\/ajtmh.2006.74.342","article-title":"Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection","volume":"74","author":"Alonso","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.pt.2018.08.001","article-title":"Genetic crosses and linkage mapping in schistosome parasites","volume":"34","author":"Anderson","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib3","series-title":"Progress in drug research Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutiques","first-page":"11","article-title":"Recent developments in the chemotherapy of schistosomiasis","volume":"16","author":"Archer","year":"1972"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004329","article-title":"Sustaining control of schistosomiasis mansoni in western cote d'Ivoire: results from a SCORE study, one year after initial praziquantel administration","volume":"10","author":"Assar\u00e9","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1590\/S0074-02762001000900025","article-title":"Replacing oxamniquine by praziquantel against Schistosoma mansoni infection in a rural community from the sugar-cane zone of Northeast Brazil: an epidemiological follow-up","volume":"96","author":"Beck","year":"2001","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature08160","article-title":"The genome of the blood fluke Schistosoma mansoni","volume":"460","author":"Berriman","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s13071-018-3132-x","article-title":"Assessment of tegumental damage to Schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy","volume":"11","author":"Buchter","year":"2018","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib8","doi-asserted-by":"crossref","first-page":"15232","DOI":"10.1002\/chem.202002856","article-title":"Multidisciplinary preclinical investigations on three oxamniquine analogues as novel drug candidates for schistosomiasis","volume":"26","author":"Buchter","year":"2020","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijpara.2016.03.006","article-title":"Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population","volume":"46","author":"Chevalier","year":"2016","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/1471-2164-15-617","article-title":"Efficient linkage mapping using exome capture and extreme QTL in schistosome parasites","volume":"15","author":"Chevalier","year":"2014","journal-title":"BMC Genom."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molbiopara.2016.03.010","article-title":"Real-time PCR for sexing Schistosoma mansoni cercariae","volume":"205","author":"Chevalier","year":"2016","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrmicro801","article-title":"Focus: schistosomiasis","volume":"2","author":"Chitsulo","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0014-4894(92)90255-9","article-title":"Schistosoma mansoni: hycanthone\/oxamniquine resistance is controlled by a single autosomal recessive gene","volume":"75","author":"Cioli","year":"1992","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0163-7258(95)00026-7","article-title":"Antischistosomal drugs: past, present \u2026 and future?","volume":"68","author":"Cioli","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S0074-02762011000200006","article-title":"Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails","volume":"106","author":"Couto","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib16","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/gb-2009-10-6-r71","article-title":"Genomic linkage map of the human blood fluke Schistosoma mansoni","volume":"10","author":"Criscione","year":"2009","journal-title":"Genome Biol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"DALYs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1389557511313040003","article-title":"The evolution of drugs on schistosoma treatment: looking to the past to improve the future","volume":"13","author":"da Rocha Pitta","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib19","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.bmc.2017.04.031","article-title":"Medicinal chemistry of antischistosomal drugs: praziquantel and oxamniquine","volume":"1","author":"da Silva","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0169-4758(98)01315-5","article-title":"Is schistosomicidal chemotherapy sub-curative? Implications for drug resistance","volume":"14","author":"Doenhoff","year":"1998","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1017\/S0031182009000493","article-title":"Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs","volume":"136","author":"Doenhoff","year":"2009","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4269\/ajtmh.1994.51.83","article-title":"Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific","volume":"51","author":"Fallon","year":"1994","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1017\/S0031182009990400","article-title":"The Schistosomiasis Control Initiative (SCI): rationale,development and implementation from 2002-2008","volume":"136","author":"Fenwick","year":"2009","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-5173(01)00917-6","article-title":"Synthesis and evaluation of new oxamniquine derivatives","volume":"21","author":"Filho","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bmc.2006.11.027","article-title":"Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs","volume":"15","author":"Filho","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0035-9203(87)90282-3","article-title":"A review of clinical experience with oxamniquine","volume":"81","author":"Foster","year":"1987","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib27","first-page":"209","article-title":"Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal","volume":"46","author":"Gryseels","year":"1994","journal-title":"Trop. Geogr. Med."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(06)69440-3","article-title":"Human schistosomiasis","volume":"368","author":"Gryseels","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008517","article-title":"An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans","volume":"14","author":"Guzman","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-3565(25)30557-4","article-title":"Long-term hepatocellular effects of hycanthone and of two other anti-Schistosomal drugs in mice infected with Schistosoma mansoni","volume":"197","author":"Haese","year":"1976","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pt.2003.11.010","article-title":"Schistosomiasis control: keep taking the tablets","volume":"20","author":"Hagan","year":"2004","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/15287397509529325","article-title":"Genetic activity spectra of some antischistosomal compounds, with particular emphasis on thioxanthenones and benzothiopyranoindazoles","volume":"1","author":"Hartman","year":"1975","journal-title":"J. Toxicol. Environ. Health"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/acsinfecdis.7b00054","article-title":"Ferrocenyl, ruthenocenyl, and benzyl oxamniquine derivatives with cross-species activity against Schistosoma mansoni and Schistosoma haematobium","volume":"3","author":"Hess","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib34","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4269\/ajtmh.1999.60.932","article-title":"Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers","volume":"60","author":"Ismail","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1590\/S0037-86821973000600008","article-title":"Estudo de uma cepa humana de Schistosoma mansoni resistente a agentes esquistossomicidas","volume":"7","author":"Katz","year":"1973","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.actatropica.2008.05.006","article-title":"Clinical therapy of schistosomiasis mansoni: the Brazilian contribution","volume":"108","author":"Katz","year":"2008","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/520522","article-title":"Lifting the burden of schistosomiasis--defining elements of infection associated disease and the benefits of antiparasite treatment","volume":"196","author":"King","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000203","article-title":"Schistosomiasis japonica: the DALYs recaptured","volume":"2","author":"King","year":"2008","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.actatropica.2009.11.012","article-title":"Parasites and poverty: the case of schistosomiasis","volume":"113","author":"King","year":"2010","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib40","first-page":"359","article-title":"Oxamniquine pharmacokinetics in healthy Kenyan African volunteers","volume":"68","author":"Kokwaro","year":"1991","journal-title":"East Afr. Med. J."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib42","doi-asserted-by":"crossref","first-page":"9336","DOI":"10.1021\/ja001923x","article-title":"The direct catalytic asymmetric three-component Mannich reaction","volume":"122","author":"List","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1139\/z03-217","article-title":"Schistosoma mansoni male\u2013female interactions","volume":"82","author":"LoVerde","year":"2004","journal-title":"Can. J. Zool."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib44","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1021\/jm0306529","article-title":"Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat","volume":"47","author":"Lu","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001494","article-title":"WormAssay: a novel computer application for whole-plate motion-based screening of macroscopic parasites","volume":"6","author":"Marcellino","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0035-9203(89)90508-7","article-title":"Binding of oxamniquine to the DNA of schistosomes","volume":"83","author":"Pica-Mattoccia","year":"1989","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0166-6851(92)90137-9","article-title":"Hycanthone resistance in schistosomes correlates with the lack of an enzymatic activity which produces the covalent binding of hycanthone to parasite macromolecules","volume":"55","author":"Pica-Mattoccia","year":"1992","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/expr.1993.1104","article-title":"Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone\/oxamniquine-resistant strains are mutated in the same gene","volume":"77","author":"Pica-Mattoccia","year":"1993","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1590\/S0074-02762006000900048","article-title":"The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase","volume":"101","author":"Pica-Mattoccia","year":"2006","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0001-706X(03)00032-9","article-title":"The impact of chemotherapy on morbidity due to schistosomiasis","volume":"86","author":"Richter","year":"2003","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jare.2012.05.002","article-title":"Novel therapeutic and prevention approaches for schistosomiasis: review","volume":"4","author":"Ridi","year":"2013","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib52","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.172.3987.1057","article-title":"Hycanthone resistance: development in Schistosoma mansoni","volume":"172","author":"Rogers","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/acsmedchemlett.8b00257","article-title":"Design, synthesis, and characterization of novel small molecules as broad range antischistosomal agents","volume":"9","author":"Rugel","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpddr.2020.04.001","article-title":"Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?","volume":"13","author":"Rugel","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"Steinmann","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib56","series-title":"Applied Biocatalysis","author":"Straathof","year":"2003"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib58","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1074\/jbc.M116.766527","article-title":"Structural and enzymatic insights into species-specific resistance to schistosome parasite drug therapy","volume":"292","author":"Taylor","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02582-16","article-title":"Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance","volume":"61","author":"Vale","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1126\/science.1243106","article-title":"Genetic and molecular basis of drug resistance and species specific drug action in schistosome parasites","volume":"342","author":"Valentim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0001-706X(03)00029-9","article-title":"Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa","volume":"86","author":"van der Werf","year":"2003","journal-title":"Acta Trop."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib62","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib63","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","article-title":"Susceptibility or resistance of praziquantel in human schistosomiasis: a review","volume":"111","author":"Wang","year":"2012","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0166-6851(89)90169-2","article-title":"Isolation of a female-specific, highly repeated Schistosoma mansoni DNA probe and its use in an assay of cercarial sex","volume":"36","author":"Webster","year":"1989","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib65","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/infdis\/jix496","article-title":"A persistent hotspot of schistosoma mansoni infection in a five-year randomized trial of praziquantel preventative chemotherapy strategies","volume":"216","author":"Wiegand","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib66","series-title":"Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis","year":"2002"},{"key":"10.1016\/j.ijpddr.2021.05.002_bib67","author":"WHO"},{"issue":"49\u201350","key":"10.1016\/j.ijpddr.2021.05.002_bib68","first-page":"585","article-title":"Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2015","volume":"91","author":"WHO","year":"2016","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.ijpddr.2021.05.002_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003286","article-title":"Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and noncomparative clinical trials","volume":"8","author":"Zwang","year":"2014","journal-title":"PLoS Neglected Trop. Dis."}],"updated-by":[{"DOI":"10.1016\/j.ijpddr.2022.01.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132072100021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132072100021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:52:56Z","timestamp":1761922376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221132072100021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":68,"alternative-id":["S221132072100021X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2021.05.002","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational approach to drug discovery for human schistosomiasis","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2021.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}